[go: up one dir, main page]

GR1008310B - Phoshinic pseudopeptide derivatives for potent inhibition of aminopeptidases of the oxytocinase subfamily of m1 aminopeptidases - Google Patents

Phoshinic pseudopeptide derivatives for potent inhibition of aminopeptidases of the oxytocinase subfamily of m1 aminopeptidases

Info

Publication number
GR1008310B
GR1008310B GR20130100582A GR20130100582A GR1008310B GR 1008310 B GR1008310 B GR 1008310B GR 20130100582 A GR20130100582 A GR 20130100582A GR 20130100582 A GR20130100582 A GR 20130100582A GR 1008310 B GR1008310 B GR 1008310B
Authority
GR
Greece
Prior art keywords
aminopeptidases
oxytocinase
derivatives
cell
phoshinic
Prior art date
Application number
GR20130100582A
Other languages
Greek (el)
Inventor
Ευστρατιος Δημητριου Στρατικος
Ευθαλια Μιχαηλ Ζερβουδη
Δημητριος Χρηστου Γεωργιαδης
Παρασκευη Αγγελου Κοκκαλα
Original Assignee
Εκεφε Δημοκριτος,
Ευστρατιος Δημητριου Στρατικος
Ευθαλια Μιχαηλ Ζερβουδη
Δημητριος Χρηστου Γεωργιαδης
Παρασκευη Αγγελου Κοκκαλα
Εθνικο Και Καποδιστριακο Πανεπιστημιο Αθηνων,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Εκεφε Δημοκριτος,, Ευστρατιος Δημητριου Στρατικος, Ευθαλια Μιχαηλ Ζερβουδη, Δημητριος Χρηστου Γεωργιαδης, Παρασκευη Αγγελου Κοκκαλα, Εθνικο Και Καποδιστριακο Πανεπιστημιο Αθηνων, filed Critical Εκεφε Δημοκριτος,
Priority to GR20130100582A priority Critical patent/GR1008310B/en
Publication of GR1008310B publication Critical patent/GR1008310B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention relates to the use of phosphinic pseudopeptide derivatives for the production of medicaments that inhibit the action of aminopeptidases of the oxytocinase sub-family of M1 aminopeptidases that includes ERAP1, ERAP2 and 1RAP (also known as PLAP). These derivatives are of formula A: (chemical formula) where R1 and R2 correspond to natural or un-natural amino acid side chains, R3 corresponds to an amino (-NH2) group or a peptide sequence bearing at their carboxy terminus a hydroxyl or an amino group and R4 corresponds to a hydrogen atom or a counterion. Applications: For the modulation of antigen processing leading to altered cell-surface antigen presentation and altered or novel cytotoxic T-cell or NK-cell responses for the treatment of viral and bacterial infections, autoimmunity or cancer immunotherapy.
GR20130100582A 2013-10-03 2013-10-03 Phoshinic pseudopeptide derivatives for potent inhibition of aminopeptidases of the oxytocinase subfamily of m1 aminopeptidases GR1008310B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GR20130100582A GR1008310B (en) 2013-10-03 2013-10-03 Phoshinic pseudopeptide derivatives for potent inhibition of aminopeptidases of the oxytocinase subfamily of m1 aminopeptidases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20130100582A GR1008310B (en) 2013-10-03 2013-10-03 Phoshinic pseudopeptide derivatives for potent inhibition of aminopeptidases of the oxytocinase subfamily of m1 aminopeptidases

Publications (1)

Publication Number Publication Date
GR1008310B true GR1008310B (en) 2014-10-02

Family

ID=50486916

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20130100582A GR1008310B (en) 2013-10-03 2013-10-03 Phoshinic pseudopeptide derivatives for potent inhibition of aminopeptidases of the oxytocinase subfamily of m1 aminopeptidases

Country Status (1)

Country Link
GR (1) GR1008310B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2755135A1 (en) * 1996-10-25 1998-04-30 Inst Nat Sante Rech Med NOVEL (ALPHA-AMINOPHOSPHINO) PEPTIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM
WO2002053169A2 (en) * 2001-01-02 2002-07-11 Keyneurotek Ag I.G. Use of dipeptylpeptidase iv and aminopeptidase-n inhibitors in the treatment of ischaemia-induced neuro-degeneration
WO2002053170A2 (en) * 2001-01-02 2002-07-11 Institut Für Medizintechnologie Magdeburg Gmbh (Imtm) Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of allergic reactions of type i according to the gell and coombs classification, and for the treatment and prevention of dermatological diseases associated with fo

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2755135A1 (en) * 1996-10-25 1998-04-30 Inst Nat Sante Rech Med NOVEL (ALPHA-AMINOPHOSPHINO) PEPTIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM
WO2002053169A2 (en) * 2001-01-02 2002-07-11 Keyneurotek Ag I.G. Use of dipeptylpeptidase iv and aminopeptidase-n inhibitors in the treatment of ischaemia-induced neuro-degeneration
WO2002053170A2 (en) * 2001-01-02 2002-07-11 Institut Für Medizintechnologie Magdeburg Gmbh (Imtm) Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of allergic reactions of type i according to the gell and coombs classification, and for the treatment and prevention of dermatological diseases associated with fo

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ALLEN M C ET AL: "RENIN INHIBITORS. SYNTHESIS OF TRANSITION-STATE ANALOGUE INHIBITORS CONTAINING PHOSPHORUS ACID DERIVATIVES AT THE SCISSILE BOND", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 32, 1 January 1989 (1989-01-01), pages 1652 - 1661, XP001094345, ISSN: 0022-2623, DOI: 10.1021/JM00127A041 *
ARTUR MUCHA ET AL: "Remarkable Potential of the [alpha]-Aminophosphonate/Phosphinate Structural Motif in Medicinal Chemistry", JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, no. 17, 8 September 2011 (2011-09-08), pages 5955 - 5980, XP055118317, ISSN: 0022-2623, DOI: 10.1021/jm200587f *
CHEN HUIXIONG ET AL: "Phosphinic derivatives as new dual enkephalin-degrading enzyme inhibitors: synthesis, biological properties, and antinociceptive activities", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 43, no. 7, 1 January 2000 (2000-01-01), pages 1398 - 1408, XP002390803, ISSN: 0022-2623, DOI: 10.1021/JM990483L *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; September 2002 (2002-09-01), YIOTAKIS, ATHANASIOS ET AL: "Diastereoselective synthesis of RXP 407, a potent pseudopeptidic inhibitor of ACE-I, able to differentiate between its two active sites", XP002724484, retrieved from STN Database accession no. 2004:28451 *
DIMITRIS GEORGIADIS ET AL: "Potent and Selective Inhibition of Zinc Aminopeptidase A (EC 3.4.11.7, APA) by Glutamyl Aminophosphinic Peptides: Importance of Glutamyl Aminophosphinic Residue in the P 1 Position +", BIOCHEMISTRY, vol. 39, no. 5, 1 February 2000 (2000-02-01), pages 1152 - 1155, XP055118525, ISSN: 0006-2960, DOI: 10.1021/bi9922345 *
E. ZERVOUDI ET AL: "Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 110, no. 49, 18 November 2013 (2013-11-18), pages 19890 - 19895, XP055118358, ISSN: 0027-8424, DOI: 10.1073/pnas.1309781110 *
HEIDI DEMAEGDT ET AL: "Binding of "AT4 receptor" ligands to insulin regulated aminopeptidase (IRAP) in intact Chinese hamster ovary cells", MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 339, no. 1-2, 1 June 2011 (2011-06-01), pages 34 - 44, XP055118511, ISSN: 0303-7207, DOI: 10.1016/j.mce.2011.03.005 *
JIRÍ JIRÁCEK ET AL: "Development of the first potent and selective inhibitor of the zinc endopeptidase neurolysin using a systematic approach based on combinatorial chemistry of phosphinic peptides.", J. BIOL. CHEM., 1 August 1996 (1996-08-01), pages 19606 - 19611, XP055118444, Retrieved from the Internet <URL:http://www.jbc.org/content/271/32/19606.full.pdf#page=1&view=FitH> [retrieved on 20140516] *
LIBOSKA R ET AL: "Synthesis of methionine- and norleucine-derived phosphinopeptides", TETRAHEDRON LETTERS, PERGAMON, GB, vol. 49, no. 39, 22 September 2008 (2008-09-22), pages 5629 - 5631, XP023902286, ISSN: 0040-4039, [retrieved on 20080712], DOI: 10.1016/J.TETLET.2008.07.062 *
MARIANNE BARLOO ET AL: "A Convenient One-Pot Preparation of Disubstituted Phosphinic Acids Derived from Simple Amino Acids and Proline", SYNTHESIS, 1 January 1995 (1995-01-01), pages 1074 - 1076, XP055118313, Retrieved from the Internet <URL:https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-1995-4050.pdf> [retrieved on 20140515] *
VERMA ET AL: "Matrix metalloproteinases (MMPs): Chemical-biological functions and (Q)SARs", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 15, no. 6, 15 February 2007 (2007-02-15), pages 2223 - 2268, XP005890893, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2007.01.011 *

Similar Documents

Publication Publication Date Title
PH12015502180A1 (en) Wt1-antigen peptide conjugate vaccine
CR20200140A (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
MX2017005199A (en) Conjugates and conjugating reagents.
MY165002A (en) Cylodextrin complexation methods for formulating peptide proteasome inhibitors
CY1120031T1 (en) N-ACYLOSULFONAMIDIS SOLUTIONAL AUTOMOBILES
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
AU2015329974A8 (en) GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
MY186349A (en) Oral care compositions and methods of use
GEP20217330B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EA201790024A1 (en) MODULATORS OF TOLL-LIKE RECEPTORS FOR HIV TREATMENT
NZ733125A (en) Isoquinoline compounds for the treatment of hiv
MX2017004838A (en) Interleukin-15 compositions and uses thereof.
EP4410374A3 (en) Cylodextrin complexation methods for formulating peptide proteasome inhibitors
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
PH12015501609A1 (en) Phenicol antibacterials
EP4414376A3 (en) Novel depsipeptide and uses thereof
IN2015DN03202A (en)
AU2015352440B2 (en) Compounds
EP4241851A3 (en) Immunogenic compositions
AU2015261096A8 (en) Process for preparing phosphorus-containing cyanohydrins
TR201819805T4 (en) FLAVAGLIN DERIVATIVES.
TR201905218T4 (en) USEFUL VITANOLIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES.
MX2015002279A (en) Synthetic pntx(19) peptide, pharmaceutical compositions and use.
MX2016003207A (en) Compositions comprising choline and derivatives thereof, uses thereof and processes for their preparation.
EA201690966A1 (en) NEW CONNECTION FOR THE TREATMENT OF HEAVY HYPOGLYCEMIA

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20141121